Alicia Bigica is the Associate Editorial Director for NeurologyLive. Prior to joining MJH Life Sciences in 2019, she helped launch leading resources for medical news in the neurology and dermatology specialties. Follow her on Twitter @aliciabigica or email her at email@example.com.
The chief medical executive at The University of Texas MD Anderson Cancer Center is expected to be named the next commissioner of the FDA by President Donald Trump.
Stephen Hahn, MD
According to reports, Stephen Hahn, MD, is expected to be named the new commissioner of the US Food and Drug Administration.
If confirmed, Hahn, who is chief medical executive and a professor in the department of radiation oncology at The University of Texas MD Anderson Cancer Center in Houston, will take over from acting commissioner Norman Sharpless, MD, who stepped in to run the agency following the resignation of Scott Gottlieb, MD, in April.
While Hahn has found much success at MD Anderson, this agency post would be his first significant interaction with policy, according to a report from The New York Times.
Notably, interim commissioner Sharpless will immediately return to his post as the director of the National Cancer Institute, while Brett Giroir, MD, an official with the Department of Health and Human Services, will step in as interim until Hahn is confirmed.
To learn more about this developing story, visit our sister site HCPLive.com.